Table 3.
Fisher’s exact test for association of single variables with progressive disease (PD) after radioligand therapy (RLT)
| Parameter | Patients (SD/PR) | Patients (PD) | 2-sided p value | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|---|---|
| Prostate-specific antigen (PSA) | |||||
| > 200 ng/mL | 5 (11%) | 8 (18%) | 0.036 | 50% (25–75%) | 83% (65–94%) |
| ≤ 200 ng/mL | 25 (54%) | 8 (17%) | |||
| Alkaline Phosphatase (ALP) | |||||
| > 135 ng/mL | 4 (9%) | 10 (22%) | 0.002 | 63% (35–85%) | 87% (69–96%) |
| ≤ 135 ng/mL | 26 (56%) | 6 (13%) | |||
| Maximum standardized uptake value (SUVmax) | |||||
| < 45 | 10 (22%) | 13 (28%) | 0.005 | 81% (54–96%) | 67% (47–83%) |
| ≥ 45 | 20 (43%) | 3 (7%) | |||
| Mean standardized uptake value (SUVmean) | |||||
| < 13 | 4 (9%) | 8 (18%) | 0.013 | 50% (25–75%) | 87% (69–96%) |
| ≥ 13 | 26 (56%) | 8 (17%) | |||
Sensitivity and specificity with their 95% confidence intervals (95% CI) are provided regarding PD vs. stable disease (SD)/partial remission (PR)